| scholarly article | Q13442814 |
| P50 | author | Christian Hölscher | Q37831053 |
| P2093 | author name string | Emilie Faivre | |
| Talib Abbas | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| memory formation | Q107596539 | ||
| synaptic plasticity | Q1551556 | ||
| type 2 diabetes | Q3025883 | ||
| P304 | page(s) | 265-271 | |
| P577 | publication date | 2009-06-30 | |
| P1433 | published in | Behavioural Brain Research | Q3619047 |
| P1476 | title | Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease | |
| P478 | volume | 205 |
| Q49113854 | A nutrigenomics approach for the study of anti-aging interventions: olive oil phenols and the modulation of gene and microRNA expression profiles in mouse brain |
| Q48254911 | Actions of exendin-4 therapy on cognitive function and hippocampal synaptic plasticity in mice fed a high-fat diet |
| Q99404602 | Alleviation of Depression by Glucagon-Like Peptide 1 Through the Regulation of Neuroinflammation, Neurotransmitters, Neurogenesis, and Synaptic Function |
| Q26996487 | Alzheimer's disease and insulin resistance: translating basic science into clinical applications |
| Q50746082 | Berberine chloride improved synaptic plasticity in STZ induced diabetic rats. |
| Q34884241 | Bidirectional metabolic regulation of neurocognitive function |
| Q34639384 | Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model |
| Q99709166 | Clinical Evidence of Antidepressant Effects of Insulin and Anti-Hyperglycemic Agents and Implications for the Pathophysiology of Depression-A Literature Review |
| Q48178356 | DPP4 Inhibitors Can Be a Drug of Choice for Type 3 Diabetes: A Mini Review |
| Q53447397 | Decreased glucagon-like peptide-1 receptor immunoreactivity in the dentate granule cell layer from adult in the gerbil hippocampus. |
| Q35532253 | Drp1-mediated mitochondrial abnormalities link to synaptic injury in diabetes model |
| Q52151966 | Early intervention with glucagon-like peptide 1 analog liraglutide prevents tau hyperphosphorylation in diabetic db/db mice. |
| Q92042716 | Effects of GLP-1 Receptor Activation on a Pentylenetetrazole-Kindling Rat Model |
| Q92005722 | Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus |
| Q28710367 | Energy intake and exercise as determinants of brain health and vulnerability to injury and disease |
| Q51362307 | Evaluation of the long-term effects of gastric inhibitory polypeptide-ovalbumin conjugates on insulin resistance, metabolic dysfunction, energy balance and cognition in high-fat-fed mice. |
| Q48864779 | Exenatide enhances cognitive performance and upregulates neurotrophic factor gene expression levels in diabetic mice |
| Q33708923 | Exendin-4 Treatment Improves LPS-Induced Depressive-Like Behavior Without Affecting Pro-Inflammatory Cytokines |
| Q28481242 | Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis |
| Q48422656 | Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces Alzheimer disease-associated tau hyperphosphorylation in the hippocampus of rats with type 2 diabetes |
| Q34745109 | Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain. |
| Q34395967 | Fertility and pregnancy-associated ß-cell proliferation in mice deficient in proglucagon-derived peptides |
| Q33609502 | GIP and GLP-1, the two incretin hormones: Similarities and differences |
| Q35200252 | GLP-1 based therapeutics: simultaneously combating T2DM and obesity. |
| Q34167980 | GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. |
| Q26997149 | GLP-1-based strategies: a physiological analysis of differential mode of action |
| Q37349843 | Glucagon-like peptide 1 receptor activation regulates cocaine actions and dopamine homeostasis in the lateral septum by decreasing arachidonic acid levels. |
| Q38868456 | Glucagon-like peptide-1 drives energy metabolism on the synaptic highway |
| Q35070673 | Glucagon-like peptide-1, diabetes, and cognitive decline: possible pathophysiological links and therapeutic opportunities. |
| Q33603384 | Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas |
| Q51021916 | Glucose-dependent insulinotropic polypeptide receptor knockout mice are impaired in learning, synaptic plasticity, and neurogenesis. |
| Q37540256 | Humans with Type-2 Diabetes Show Abnormal Long-Term Potentiation-Like Cortical Plasticity Associated with Verbal Learning Deficits |
| Q58608318 | Impact of rye-based evening meals on cognitive functions, mood and cardiometabolic risk factors: a randomized controlled study in healthy middle-aged subjects |
| Q37894864 | Incretin-based therapies |
| Q27008997 | Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome |
| Q47102484 | Interactions between metabolic, reward and cognitive processes in appetite control: Implications for novel weight management therapies. |
| Q48488584 | Linagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Mitigates Cognitive Deficits and Pathology in the 3xTg-AD Mouse Model of Alzheimer's Disease. |
| Q26860246 | Link between type 2 diabetes and Alzheimer's disease: from epidemiology to mechanism and treatment |
| Q38324750 | Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice. |
| Q47107585 | Liraglutide restores chronic ER stress, autophagy impairments and apoptotic signalling in SH-SY5Y cells |
| Q35007766 | Long-Term Potentiation at CA3-CA1 Hippocampal Synapses with Special Emphasis on Aging, Disease, and Stress |
| Q24562763 | Metabolic dysfunction in Alzheimer's disease and related neurodegenerative disorders |
| Q42098016 | Microbiota modulation counteracts Alzheimer's disease progression influencing neuronal proteolysis and gut hormones plasma levels. |
| Q38974881 | Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer's disease pathology |
| Q35568177 | Modulation of hippocampal neural plasticity by glucose-related signaling |
| Q48061475 | Neurochemical modulation involved in the beneficial effect of liraglutide, GLP-1 agonist on PTZ kindling epilepsy-induced comorbidities in mice |
| Q90236862 | Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer's and Parkinson's Diseases |
| Q48358888 | Neuroprotective actions of glucagon-like peptide-1 in differentiated human neuroprogenitor cells |
| Q36166654 | Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders |
| Q26777654 | New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders |
| Q38668948 | Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer's Disease and Other Neurodegenerative Diseases |
| Q41986529 | Obesity as a risk factor for Alzheimer's disease: weighing the evidence |
| Q34290086 | Obesity-Related Hormones in Low-Income Preschool-Age Children: Implications for School Readiness |
| Q35558707 | Obesity-associated biomarkers and executive function in children |
| Q36339320 | PPG neurons of the lower brain stem and their role in brain GLP-1 receptor activation. |
| Q59812434 | Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function |
| Q38926789 | Potential effects of current drug therapies on cognitive impairment in patients with type 2 diabetes |
| Q26774021 | Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus |
| Q47266756 | Presynaptic GLP-1 receptors enhance the depolarization-evoked release of glutamate and GABA in the mouse cortex and hippocampus |
| Q64102382 | Regulation of Memory Function by Feeding-Relevant Biological Systems: Following the Breadcrumbs to the Hippocampus |
| Q41636096 | RhGLP-1 (7-36) protects diabetic rats against cerebral ischemia-reperfusion injury via up-regulating expression of Nrf2/HO-1 and increasing the activities of SOD. |
| Q28083039 | Role of anti-diabetic drugs as therapeutic agents in Alzheimer's disease |
| Q26824141 | Running forward: new frontiers in endurance exercise biology |
| Q48379621 | Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline |
| Q37685201 | Subcutaneous liraglutide ameliorates methylglyoxal-induced Alzheimer-like tau pathology and cognitive impairment by modulating tau hyperphosphorylation and glycogen synthase kinase-3β |
| Q35738734 | Synergistic exacerbation of mitochondrial and synaptic dysfunction and resultant learning and memory deficit in a mouse model of diabetic Alzheimer's disease |
| Q37900307 | Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes |
| Q37811420 | The Role of GLP-1 in Neuronal Activity and Neurodegeneration |
| Q47111896 | The Role of Glucagon-Like Peptide 1 (GLP1) in Type 3 Diabetes: GLP-1 Controls Insulin Resistance, Neuroinflammation and Neurogenesis in the Brain |
| Q42715682 | The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer's disease. |
| Q51011184 | The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. |
| Q50050282 | The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease. |
| Q26768527 | The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action |
| Q33868403 | The impact of dietary energy intake on cognitive aging |
| Q37830311 | The role of G protein-coupled receptors in the pathology of Alzheimer's disease |
| Q35199055 | Treadmill exercise prevents diabetes-induced increases in lipid peroxidation and decreases in Cu,Zn-superoxide dismutase levels in the hippocampus of Zucker diabetic fatty rats |
| Q95643642 | Type 2 diabetes and cognitive dysfunction-towards effective management of both comorbidities |
| Q30494084 | Uncovering molecular biomarkers that correlate cognitive decline with the changes of hippocampus' gene expression profiles in Alzheimer's disease |
| Q53427297 | [Diabetes mellitus and cognitive decline]. |
Search more.